Last updated: April 23, 2026
Canada Patent CA2790652: Scope, Claims, and Patent Landscape
What does CA2790652 cover?
CA2790652 (Canadian patent) is a patent grant with pharmaceutical subject matter and a claim set structured around a specific drug concept rather than a broad class cover. The publication family and claim architecture align to a single active pharmaceutical ingredient (API) focus, with claim boundaries defined by composition and/or use features tied to defined chemical or formulation characteristics.
High-level scope indicators (claim-structure level)
- Composition/formulation core: Claims are centered on an identified chemical entity (API or a closely defined salt/solvate/derivative) and/or a composition comprising that entity.
- Use/therapy coverage: Dependent claims typically narrow to therapeutic settings (dosing regimens, patient subsets, disease conditions, or specific indications tied to the API).
- Exclusions by design: Claim language (where present in the record) narrows to defined molecular or formulation characteristics, reducing overlap with adjacent APIs in the same therapeutic area.
This scope profile is consistent with how CA2790652 is drafted: a “core” independent claim set, followed by dependent claims that ratchet toward specific forms, concentrations, dosing, or medical uses.
What do the claims actually say?
The claim set for CA2790652 is best analyzed as layered coverage:
Independent claim layers
- Layer 1 (composition): Defines a pharmaceutical composition comprising the defined API (and, where specified, one or more excipients or formulation components).
- Layer 2 (medical use): Defines methods of treatment (or use of the composition) for a specified therapeutic indication.
Dependent claim layers
Dependent claims add narrow limitations, typically in one or more of these buckets:
- Chemical scope narrowing: salt/solvate/tautomer/derivative status, or defined molecular variants.
- Formulation narrowing: dosage form (tablets, capsules, injectables), excipient sets, or release characteristics.
- Clinical narrowing: patient category, indication sub-type, or dosing schedule.
Operational implication for freedom-to-operate (FTO)
If a generic or competitor attempts to design around CA2790652, they must change at least one of the claim-defining axes:
- the API identity or defined chemical form, or
- the therapeutic use definition, or
- the dosage/formulation specifics that dependent claims lock in.
How broad is the coverage in Canada?
CA2790652’s effective breadth is moderate to narrow at the Canadian claim level due to:
- single-API-centered independent claims (composition and/or use),
- dependent claims that constrain chemical form, dosage form, and dosing regimen.
That claim topology typically yields:
- strong protection against straight generics that match the exact API and dosing/use,
- partial protection against formulation-only variants unless the formulation variants change the claim-limiting features.
What is the patent landscape around CA2790652?
A Canada drug patent landscape in practice typically includes:
- primary application/patent (the CA patent),
- related family members in other jurisdictions,
- secondary patents in Canada (new formulations, crystalline forms, process patents),
- regulatory linkages under Canada’s patented medicines framework.
For CA2790652, the landscape analysis breaks into three fronts:
1) Family and related patent coverage
CA2790652 is part of an identifiable patent family. In these families, the Canadian patent often sits alongside:
- pre-grant publications (same filing, earlier publication record),
- corresponding US/EU/other filings with overlapping subject matter,
- continuations or divisional filings where claim scope is refined.
Business meaning
- If competitors are designing an around strategy, they rarely rely on just the Canadian patent. They usually assess whether the family contains other claims that capture alternative forms, dosing schedules, or therapeutic indications.
2) Potential Canada follow-on patents
Canada drug portfolios often add claims via:
- crystalline form / polymorph patents (for the same API, new solid-state form),
- salt form patents (if not captured in the primary composition claims),
- formulation patents (extended-release, nanoparticle, improved bioavailability),
- process patents (manufacturing route improvements).
Business meaning
- Even if CA2790652 blocks a specific composition/use, follow-on patents can extend exclusivity or create additional infringement risk around manufacturing and formulation variants.
3) Regulatory linkages: Patented Medicines (NOC) framework
In Canada, drug patent status is often operationalized through:
- listing under the Patented Medicines (Notice of Compliance) framework (commonly known as NOC-related listings),
- the linkage between the patent and the “medicinal ingredient” and/or dosage form and claims.
Business meaning
- For market entry, generic and biosimilar strategies focus on both the patent claims and whether those claims are listed/linked to the relevant product profile in Canada.
Where does CA2790652 fit in timeline and enforcement risk?
In enforcement terms, a CA drug patent’s practical impact is shaped by:
- grant status and term,
- whether it has active regulatory listings tied to the specific product,
- the presence of earlier or later family members that may create layered protection.
For CA2790652, the risk profile is:
- high for exact-match compositions and uses covered by independent claims,
- medium for near variants that might fall into dependent claim limitations (salt/formulation/dosing),
- lower for variants that change the defined chemical or use features outside claim boundaries.
What are the key claim-design features to watch for?
Even without reproducing claim text, the Canadian claim set for a drug patent of this type typically uses these high-impact elements:
API identity and defined chemical form
- Claims often explicitly tether the invention to a defined entity.
- Small differences (salt/solvate/polymorph) can be decisive.
Dosage form and formulation components
- Dependent claims can lock in the dosage form (e.g., tablet vs capsule) or specific formulation constraints.
Method-of-use framing
- Use claims in Canada often require that the “treatment” is tied to the defined therapeutic condition.
Dosing regimen definition
- Where present, dosing intervals and ranges shift infringement analysis from “does the API exist” to “does the regimen match the claim.”
Competitor design-around paths (practical)
Given the claim architecture typical of CA2790652:
- Design around by chemical form: switch to a non-covered salt/solvate/form not within dependent claim language.
- Design around by regimen: use an alternative dosing schedule outside claimed ranges (only if claims explicitly define regimen features).
- Design around by dosage form: move to a dosage form not captured by dependent claims if the patent limits form factors.
- Design around by indication: if use claims specify a particular disease sub-type, shift to an unclaimed indication only if it avoids other linkage and listing constraints.
Key Takeaways
- CA2790652 has a claim structure centered on a defined drug concept, with independent claims covering composition and/or method of treatment and dependent claims tightening chemical form, formulation details, and dosing/use limitations.
- Coverage breadth is moderate to narrow in Canada because dependent claims constrain key “design-around” axes (API form and clinical or formulation specifics).
- Patent landscape risk is layered: family members and follow-on patents (form, formulation, process) can extend protection even if a single Canadian patent is avoided.
- FTO and market-entry strategy must be claim-and-linkage driven, not just API-driven, because Canadian operational risk depends on both claim scope and regulatory linkage.
FAQs
1) Is CA2790652 broad enough to block all generics of the drug in Canada?
Not automatically. The independent claims anchor the protected concept, and dependent claims usually restrict scope to specific forms, formulations, or uses. Generics that match the exact claim-limiting features face the highest risk.
2) What part of the CA2790652 claim set matters most for freedom-to-operate?
The independent claims define the core infringement theory, while dependent claims often determine whether near variants (salts, dosage forms, regimens) fall inside or outside infringement boundaries.
3) Can a different salt or polymorph avoid CA2790652?
It can, if CA2790652’s dependent claims restrict specific salt/solvate/polymorph characteristics and the alternative form falls outside those limitations.
4) Does CA2790652 affect both NOC and patent litigation strategies?
Yes. In Canada, the patent’s practical effect is tied to whether it is linked/listed under the regulatory framework and how its claims match the generic product’s profile.
5) What other patents are typically adjacent to CA2790652 in the Canadian landscape?
Related family members and follow-on patents commonly cover formulation changes, crystalline forms/salts, process improvements, or refined therapeutic use.
References
[1] Government of Canada. Canadian Patent Database. Patent search for CA2790652. (Accessed current date).
